2-Week Study In People With Nonalcoholic Fatty Liver Disease

Completed · Phase 1 · Has a placebo group

Conditions studied: Non-alcoholic Steatohepatitis, Non-alcoholic Fatty Liver Disease

In brief

2-week study in people with nonalcoholic fatty liver disease. Study drug at 1 of 2 doses, or placebo, will be given for 14 days. Blood samples, heart monitoring, vital signs, and imaging procedures will be performed.

Key facts

Study ID

NCT03513588

Run by

Pfizer

People needed

48

Starts

2018-06-21

Expected to finish

2019-04-04

Last updated by the study team

2020-03-13

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• controlled attenuation parameter greater than or equal to 260 dB/m via FibroScan
• liver fat greater than or equal to 6% via MRI

You may not qualify if…

• Chronic liver disease
• Type 2 diabetes requiring drug treatment
• Unable to undergo MRI
• History of heart attack or stroke

Where it is running

• Anaheim Clinical Trials, LLC — Anaheim, California, United States
• New Haven Clinical Research Unit — New Haven, Connecticut, United States
• Qps-Mra, Llc — South Miami, Florida, United States
• PPD Development, LP — Las Vegas, Nevada, United States
• High Point Clinical Trials Center — High Point, North Carolina, United States
• Clinical Trials of Texas, Inc. — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.